Incyte, TG's PI3K Inhibitors Show Safety Advantage In Indolent NHL
Data At ASH Show Strong Efficacy, Favorable Safety For Umbralisib, Parsaclisib
Neither TG's UNITY-NHL nor Incyte's CITADEL-203 study reported any fatal adverse events - a problem for which Gilead and Verastem's PI3K inhibitors carry boxed warnings.
